BeiGene announced the U.S. FDA has approved a label update for BRUKINSA to include superior progression-free survival results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA in previously treated patients with relapsed or refractory chronic lymphocytic leukemia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BGNE:
- BeiGene treatment of mantle cell lymphoma granted FDA orphan designation
- BeiGene to present new data on hematology portfolio and pipeline
- BeiGene treatment of multiple myeloma granted orphan designation
- BeiGene, Ensem Therapeutics partner on CDK2 inhibitor
- BeiGene receives European Commission approval for BRUKINSA
